Soleus Capital Management’s Revolution Medicines RVMD Stock Holding History

Soleus Capital Management’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,000	Closed	-$368K	–	103
2025 Q2	$368K	Sell	10,000 -74,784	-88%	-$2.87M	0.02%	91
2025 Q1	$3M	Sell	84,784 -116,300	-58%	-$4.72M	0.22%	57
2024 Q4	$8.8M	Sell	201,084 -503,500	-71%	-$25.4M	0.55%	43
2024 Q3	$32M	Sell	704,584 -151,594	-18%	-$6.6M	2.47%	13
2024 Q2	$33.2M	Buy	856,178 +127,478	+17%	+$4.76M	2.93%	7
2024 Q1	$23.5M	Buy	728,700 +476,700	+189%	+$14.1M	1.74%	15
2023 Q4	$7.23M	Buy	+252,000	New	+$6.06M	0.8%	39
2021 Q3	–	Sell	-125,700	Closed	-$3.99M	–	82
2021 Q2	$3.99M	Buy	125,700 +68,500	+120%	+$2.39M	0.61%	34
2021 Q1	$2.62M	Buy	+57,200	New	+$2.57M	0.47%	43

Other funds holding RVMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Soleus Capital Management's RVMD Position: Q3 2025 in Review

Soleus Capital Management sold out of Revolution Medicines (RVMD) in Q3 2025, closing a stake of 10,000 shares — an estimated $368K sold.

Soleus Capital Management first reported a position in RVMD in Q1 2021 and held it in 9 quarters. The position peaked at $33.2M in Q2 2024. 323 funds tracked by Wall St. Rank hold RVMD as of Q3 2025.

Soleus Capital Management reported no remaining Revolution Medicines position as of Q3 2025 after selling out during the quarter.
Soleus Capital Management sold 10,000 Revolution Medicines shares in Q3 2025, an estimated $368K.
Soleus Capital Management first reported a position in Revolution Medicines in Q1 2021 and held it in 9 quarters.
Soleus Capital Management's Revolution Medicines position peaked at $33.2M in Q2 2024.
323 funds tracked by Wall St. Rank held Revolution Medicines as of Q3 2025.

Based on Soleus Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.